UMB Bank n.a. Reduces Position in Amgen Inc. (NASDAQ:AMGN)

UMB Bank n.a. trimmed its holdings in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 6.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 32,685 shares of the medical research company's stock after selling 2,233 shares during the period. UMB Bank n.a.'s holdings in Amgen were worth $8,519,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Capital Performance Advisors LLP purchased a new stake in Amgen in the third quarter worth approximately $25,000. Hershey Financial Advisers LLC bought a new stake in shares of Amgen in the second quarter worth $30,000. Legacy Investment Solutions LLC purchased a new stake in Amgen during the third quarter valued at $29,000. Matrix Trust Co bought a new position in Amgen in the third quarter valued at about $36,000. Finally, Livelsberger Financial Advisory purchased a new position in Amgen in the third quarter worth about $56,000. Institutional investors own 76.50% of the company's stock.

Amgen Price Performance

Shares of AMGN stock traded up $2.68 on Monday, reaching $272.11. The company's stock had a trading volume of 3,244,015 shares, compared to its average volume of 3,140,853. The stock's fifty day simple moving average is $273.95 and its 200-day simple moving average is $307.18. Amgen Inc. has a 1 year low of $253.30 and a 1 year high of $346.85. The company has a market capitalization of $146.27 billion, a price-to-earnings ratio of 34.84, a price-to-earnings-growth ratio of 2.68 and a beta of 0.56. The company has a current ratio of 1.32, a quick ratio of 0.96 and a debt-to-equity ratio of 7.55.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its quarterly earnings data on Wednesday, October 30th. The medical research company reported $5.58 EPS for the quarter, topping analysts' consensus estimates of $5.11 by $0.47. The business had revenue of $8.50 billion during the quarter, compared to analysts' expectations of $8.50 billion. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The business's revenue was up 23.2% on a year-over-year basis. During the same period last year, the company posted $4.96 EPS. Analysts forecast that Amgen Inc. will post 19.57 earnings per share for the current fiscal year.

Amgen Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, February 14th will be given a dividend of $2.38 per share. The ex-dividend date of this dividend is Friday, February 14th. This is an increase from Amgen's previous quarterly dividend of $2.25. This represents a $9.52 dividend on an annualized basis and a yield of 3.50%. Amgen's dividend payout ratio is 121.90%.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the stock. Citigroup reduced their price target on shares of Amgen from $335.00 to $310.00 in a research report on Wednesday, November 27th. Sanford C. Bernstein assumed coverage on shares of Amgen in a research report on Thursday, October 17th. They issued an "outperform" rating and a $380.00 price target on the stock. Bank of America reissued an "underperform" rating and set a $256.00 price objective on shares of Amgen in a research report on Tuesday, December 10th. Jefferies Financial Group reaffirmed a "buy" rating and issued a $380.00 target price on shares of Amgen in a report on Tuesday, November 12th. Finally, TD Cowen raised their price objective on Amgen from $381.00 to $383.00 and gave the stock a "buy" rating in a research note on Monday, October 21st. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $314.91.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.